Blood cancer Archives

News and Trends 9 Jun 2023

Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication

Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician, a survey by Swiss-based pharmaceutical Novartis has revealed. The Survey of Unmet Needs…

June 9, 2023 - 4 minutesmins - By Roohi Mariam Peter

News and Trends 10 May 2023

Scientists create first CRISPR-based drug candidate targeting the microbiome

A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve…

May 10, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

New promising targeted drug for a rare leukemia

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option…

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 31 Jan 2023

Singapore researchers use old drug as new acute leukemia treatment

A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, has revisited an existing drug to combat a type of blood…

January 31, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

First leukemia patient dosed with SMART101

Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial SloanKettering…

January 24, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

First CAR-T technology trial for patients with T-cell leukemia subtype authorized

The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial led by the company OneChain Immunotherapeutics (OCI). It will be the world’s first trial with…

December 22, 2022 - 4 minutesmins - By Jim Cornall

In Depth 20 Dec 2022

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics' Ebvallo marks the first immunotherapy based on T cells sourced from…

December 20, 2022 - 6 minutesmins - By Jonathan Smith

blood cancer disease model, multi-omics, CAR-T, oncology

Deciphering blood cancer complexity with multi-omics and patient-relevant disease models

A new case of blood cancer gets diagnosed approximately every three minutes in Western countries. Although the last three decades have seen considerable progress in treating blood cancers, this heterogeneous…

December 5, 2022 - 7 minutesmins - By External Contributor

News and Trends 3 Oct 2022

Estrella and TradeUP merge to become publicly traded company

Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction,…

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Sep 2022

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors…

September 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 18 Jul 2022

Positive results for drug combination used to treat rare blood cancer

Exploratory analysis of anti-cancer drug, navitoclax, combined with ruxolitinib - a medication for the treatment of intermediate or high-risk myelofibrosis (MF) - has given positive results in a study. The…

July 18, 2022 - 3 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

AstraZeneca adds to its treatments for blood cancer with $100M deal

AstraZeneca announced today (July 5) it has agreed to buy a company working on a cancer cure. The company will hand over $100 million for TeneoTwo, Inc. in an upfront…

July 5, 2022 - 2 minutesmins - By Liza Laws

CAR-T cell therapy, cancer therapy, cell therapy

Combination Therapies: Opportunities for Improved CAR-T Cell Therapy?

Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However, CAR-T therapy still faces limitations. How can combination therapy enhance its success in treating cancer?…

March 10, 2022 - 6 minutesmins - By Alexander Burik

News and Trends 22 Oct 2021

Gene-Edited T Cell Therapy Players Battle Safety Doubts

Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused all clinical development following the detection of an unexpected genetic change in a clinical trial.…

October 22, 2021 - 5 minutesmins - By Anita Chakraverty

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is…

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

morphosys genmab janssen cancer immunotherapy

News and Trends 28 Jan 2019

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began…

January 28, 2019 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Jan 2019

Update: French Biotech Considers Takeover After Failed Leukemia Drug Trial

Update (14/01/2019): An anonymous French company on Euronext has made an offer to take over Hybrigenics Pharma. This takeover bid could be good news for Hybrigenics, which has been planning…

January 14, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 28 May 2018

Genmab and Janssen Suffer Combination Therapy Setback

Janssen will discontinue a Phase I study testing Danish biotech Genmab's blood cancer blockbuster daratumumab combined with a candidate checkpoint inhibitor in patients with multiple myeloma. Janssen, which obtained the…

May 28, 2018 - 2 minutesmins - By Alexander Burik

Interview 21 May 2018

Engineering Red Blood Cells to Fight the Most Severe Cancers

Our very own red blood cells could soon become a treatment for some of the most severe forms of cancer; After a long journey of ups and downs, Erytech is…

May 21, 2018 - 6 minutesmins - By Alexander Burik

News and Trends 19 Apr 2018

“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“

Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. …

April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

The Biotech Perspective 2023

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering